These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 32627223)
41. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW; JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763 [TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction. Lee CH; Tsai TH; Lin CJ; Hsueh SK; Chung WJ; Cheng CI Am J Cardiovasc Drugs; 2019 Jun; 19(3):325-334. PubMed ID: 30746615 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Peng W; Zhang Y; Li X; Lin Y J Cardiovasc Pharmacol; 2023 Feb; 81(2):134-140. PubMed ID: 36410041 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis. Zhao X; Ai G; Qiu M; Wang X; Zhang L; Yang X; Liu Y; Xu P; Zhang J; Gu C; Zhou M; Hao Y; Zhao D; Han Y; Int J Cardiol; 2020 Jul; 310():1-8. PubMed ID: 32307186 [TBL] [Abstract][Full Text] [Related]
47. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052 [TBL] [Abstract][Full Text] [Related]
48. Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction. Ko D; Evans PT; Lin KJ; Pande AN; Cervone A; Lee SB; Cheng S; Tsacogianis T; Glynn RJ; Kim DH J Am Heart Assoc; 2024 Aug; 13(15):e034529. PubMed ID: 39056329 [TBL] [Abstract][Full Text] [Related]
49. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Li YS; Wang SH; Hwang SJ; Yang YH; Hsieh KP Br J Clin Pharmacol; 2022 Jan; 88(1):145-154. PubMed ID: 34080719 [TBL] [Abstract][Full Text] [Related]
50. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
51. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798 [TBL] [Abstract][Full Text] [Related]
52. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis. Hong J; Turgeon RD; Pearson GJ Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764 [No Abstract] [Full Text] [Related]
53. Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China. Qiu M; Na K; Qi Z; Zhou H; Li P; Xu K; Wang B; Liu H; Li J; Li Y; Han Y Mayo Clin Proc; 2023 Jul; 98(7):1021-1032. PubMed ID: 37419570 [TBL] [Abstract][Full Text] [Related]
54. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763 [TBL] [Abstract][Full Text] [Related]
55. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan. Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213 [TBL] [Abstract][Full Text] [Related]
56. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573 [TBL] [Abstract][Full Text] [Related]
57. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117 [TBL] [Abstract][Full Text] [Related]
58. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. Wu B; Lin H; Tobe RG; Zhang L; He B J Comp Eff Res; 2018 Mar; 7(3):281-291. PubMed ID: 29094604 [TBL] [Abstract][Full Text] [Related]
59. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'. Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Wu H; Xiang X; Li D; Shen S; Li X Curr Pharm Des; 2020; 26(46):5988-5997. PubMed ID: 32534561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]